The CRC Digest

Curated CRC research — accessible, accurate, actionable

Friday, May 29, 2026

1 min read

Was this forwarded to you? Read on the web or subscribe free

IMPORTANT: The CRC Digest curates and summarizes publicly available research for informational and educational purposes only. Nothing in this newsletter constitutes medical advice, diagnosis, or treatment recommendation. The information provided should not be used as a substitute for professional medical advice. Always seek the guidance of your physician or other qualified health provider with any questions regarding a medical condition or treatment. Content is generated with AI assistance and reviewed by the editorial team. We are not medical professionals. Individual results, treatments, and outcomes vary.

CRC Research Update

• ◇ ctDNA clearance predicts outcomes with sotorasib plus panitumumab in KRAS G12C colorectal cancer

  Phase 3 CodeBreaK 300 data show that circulating tumor DNA clearance serves as an early indicator of treatment efficacy and prognosis in patients with KRAS G12C–mutated metastatic colorectal cancer receiving the combination. (Journal of Clinical Oncology)

• ◆ CheckMate 8HW subgroup analysis reveals treatment-free survival in MSI-H/dMMR colorectal cancer

  Phase 3 trial data comparing nivolumab plus ipilimumab versus nivolumab alone include new analyses of treatment-free status and outcomes in long-term survivors with microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer. (Journal of Clinical Oncology)

• ◇ Prior anti-EGFR therapy and ctDNA profiling inform HER2-targeted treatment in colorectal cancer

  Integrated analysis of TRIUMPH and MyPathway trials shows that baseline circulating tumor DNA profiling and prior anti-EGFR therapy affect the efficacy of pertuzumab plus trastuzumab in HER2-amplified metastatic colorectal cancer. (ESMO Open)

• ● American Cancer Society updates colorectal cancer screening guideline to include new molecular tests

  The 2026 guideline update reaffirms screening starting at age 45 and adds newly FDA-approved molecular-based tests—a multitarget stool RNA test, a next-generation mt-sDNA test, and a blood-based cell-free DNA assay—to the list of screening options. (CA: A Cancer Journal for Clinicians)

Stay informed—research moves forward every day.